CymaBay Therapeutics Inc. (CBAY)
NASDAQ: CBAY
· Real-Time Price · USD
32.48
0.01 (0.03%)
At close: Mar 21, 2024, 9:00 PM
CymaBay Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 57K | n/a | 31.02M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 56K | 215K | 211K | 199K | 185K | 182K | 174K | n/a | n/a | n/a | n/a | n/a |
Gross Profit | 1K | -215K | 30.8M | -199K | -185K | -182K | -174K | n/a | n/a | n/a | n/a | n/a |
Operating Income | -42.5M | -32.21M | -99K | -26.88M | -23.48M | -21.36M | -23.77M | -24.5M | -24.51M | -22.19M | -23.27M | -17.62M |
Interest Income | 5.68M | 3.17M | 2.63M | 2.01M | 919K | 677K | 321K | 98K | 27K | 29K | 44K | 67K |
Pretax Income | -41.9M | -33.88M | -808K | -28.78M | -26.63M | -24.5M | -27.09M | -27.77M | -26.54M | -22.68M | -23.22M | -17.55M |
Net Income | -41.9M | -33.88M | -808K | -35.08M | -36.38M | -27.65M | -30.42M | -31.04M | -26.54M | -22.68M | -23.22M | -17.55M |
Selling & General & Admin | 19.81M | 12.24M | 11.58M | 8.32M | 7.25M | 5.9M | 5.88M | 6.09M | 6.1M | 5.18M | 6.52M | 5.24M |
Research & Development | 22.69M | 19.96M | 19.54M | 18.55M | 16.23M | 15.46M | 17.89M | 18.41M | 18.41M | 17.01M | 16.75M | 12.38M |
Other Expenses | -3K | -2K | n/a | n/a | n/a | n/a | 2K | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 42.5M | 32.21M | 31.11M | 26.88M | 23.48M | 21.36M | 23.77M | 24.5M | 24.51M | 22.19M | 23.27M | 17.62M |
Interest Expense | 5.08M | 4.84M | 4.62M | 4.4M | 4.08M | 3.82M | 3.65M | 3.37M | 2.06M | 522K | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 42.55M | 32.21M | 31.11M | 26.88M | 23.48M | 21.36M | 23.77M | 24.5M | 24.51M | 22.19M | 23.27M | 17.62M |
Income Tax Expense | n/a | -215K | n/a | 6.31M | 9.75M | 3.14M | 3.33M | 3.27M | n/a | 29K | n/a | n/a |
Shares Outstanding (Basic) | 113.32M | 105.72M | 102.15M | 97.97M | 87.81M | 84.68M | 84.68M | 86.78M | 69.02M | 69.02M | 68.99M | 68.95M |
Shares Outstanding (Diluted) | 113.32M | 105.72M | 102.15M | 97.97M | 87.81M | 87.8M | 87.8M | 87.8M | 69.02M | 69.02M | 68.99M | 68.95M |
EPS (Basic) | -0.37 | -0.32 | -0.01 | -0.36 | -0.41 | -0.33 | -0.36 | -0.36 | -0.38 | -0.33 | -0.34 | -0.25 |
EPS (Diluted) | -0.37 | -0.32 | -0.01 | -0.36 | -0.41 | -0.31 | -0.35 | -0.35 | -0.38 | -0.33 | -0.34 | -0.25 |
EBITDA | -42.44M | -32.21M | 4.02M | -24.18M | -23.29M | -20.5M | -23.27M | -24.23M | -24.31M | -21.98M | -23.09M | -17.45M |
EBIT | -36.82M | -38.73M | 3.81M | -24.38M | -22.56M | -20.69M | -23.45M | -24.4M | -24.48M | -22.16M | -23.27M | -17.62M |
Depreciation & Amortization | 56K | 215K | 211K | 2.7M | 919K | 859K | 497K | 267K | 173K | 176K | 175K | 164K |